Assessment of the Effectiveness of an Integrative Therapy for Cannabis Misuse in Adolescents
NCT ID: NCT05765409
Last Updated: 2023-03-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
100 participants
INTERVENTIONAL
2023-02-15
2025-06-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The secondary objectives of the study are:
To assess the effectiveness of the TIMCA, in comparison to the TAU, on: (1) Relationship quality with parents, (2) Relationship quality with closest friend, (3) Emotional regulation strategies, (4) Depressive symptomatology, (5) Anxiety symptomatology, (6) Adherence to therapy
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
NCT06395467
Maximizing the Efficacy of Cognitive Behavior Therapy and Contingency Management
NCT00350649
Integrated Treatment of Marijuana Abuse for HIV+ Youth
NCT00683488
Treatment for Adolescent Marijuana Abuse
NCT00580671
Cannabis Use Disorder Treatment Study
NCT04567394
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This randomized, single-blind, two-arm, parallel, multicenter trial postulates that participants in the TIMCA group will have better outcomes than those in the Treatment As Usual (TAU) group in terms of cannabis use, quality of relationship with others, emotional regulation strategies, as well as anxiety-depressive symptomatology (during therapy, at the end of therapy, and at four weeks after the end of therapy).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
This is a prospective, randomized, single-blind, two-arm, parallel, multicenter study to evaluate the non-inferiority of an Integrative Therapy for Adolescent Cannabis Misuse (TIMCA) compared to the Treatment As Usual (TAU) control group using an Adaptive Group-Sequential non Inferiority Study Design. Two interim analyses are planned (when 30 and 60 subjects have completed the study).
Both interventions will take place under similar conditions: 10 sessions, once a week, delivered by clinical psychologists who will be supervised.
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TIMCA
The intervention will combine elements of motivational interviewing, cognitive and behavioral therapy and an attachment-based intervention. Sessions with both the adolescent and his parents are planned.
TIMCA
TIMCA is an individual therapy that will include the parents at certain points in the therapy .
It will consist of two sessions of MI, two sessions of CBT, five sessions of ABI and one final session of summary to conclude the therapy.
Out of 10 sessions, there will be three with the parents and the adolescent together.
Treatment as Usual
The comparator, an active control, will be Treatment As Usual" (TAU) group, i.e., the therapy usually practiced in the services. Given the multiplicity of investigating centers and the different treatments offered according to the patient's problems, it seems difficult to choose a single reference treatment for the control arm. Each investigating center undertakes to adopt the treatment that seems most effective and appropriate for each patient
Treatment as Usual
TAU will consist of several approaches including analytical, cognitive-behavioral , intepersonal psychotherapy.
Each therapist will be asked to specify the approach used as well as the therapeutic axes.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TIMCA
TIMCA is an individual therapy that will include the parents at certain points in the therapy .
It will consist of two sessions of MI, two sessions of CBT, five sessions of ABI and one final session of summary to conclude the therapy.
Out of 10 sessions, there will be three with the parents and the adolescent together.
Treatment as Usual
TAU will consist of several approaches including analytical, cognitive-behavioral , intepersonal psychotherapy.
Each therapist will be asked to specify the approach used as well as the therapeutic axes.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Consulting as an outpatient center:
* Fulfilling the criteria for Cannabis Use Disorder (CUD) according to DSM 5 criteria (mild, moderate or severe)
* Fluent in oral and written French
* Benefiting from a social security plan
* Having signed their consent to participate (and their legal representative if applicable).
Exclusion Criteria
* With a substance use disorder other than cannabis and tobacco,
* Already engaged in another form of therapy
* Pregnant women at the time of inclusion
* Participants of age subject to a legal protection measure or unable to express their consent
14 Years
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier St Anne
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hassan Rahioui, Doctor
Role: PRINCIPAL_INVESTIGATOR
GHU Paris Psychiatry & Neurosciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GHU Paris Psychiatrie & Neurosciences
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D22-P019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.